WO2026115567 - SUSTAINED RELEASE FORMULATIONS OF MILVEXIAN
National phase entry is expected:
Publication Number
WO/2026/115567
Publication Date
04.06.2026
International Application No.
PCT/IN2025/051929
International Filing Date
25.11.2025
Title **
[English]
SUSTAINED RELEASE FORMULATIONS OF MILVEXIAN
[French]
FORMULATIONS À LIBÉRATION PROLONGÉE DE MILVEXIAN
Applicants **
DR. REDDY’S LABORATORIES LIMITED
Inventors
JHA, Romesh
BHATTACHARYA, Saswati
ARORA, Sachin
HANDA, Ajay Kumar
GAUTAM, Anirudh
KOLLIPARA, Sivacharan
UPPULURI, Chandra Teja
Priority Data
202441092145
26.11.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2164 | |
| EPO | Filing, Examination, Granting | 12624 | |
| Japan | Filing, Examination, Granting | 2243 | |
| South Korea | Filing, Examination, Granting | 2237 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,008
Contact Us
Abstract[English]
The present invention relates to novel sustained release formulation of milvexian, which are useful for the treatment or prevention of thromboembolic events. The invention is particularly suitable for once-a-day administration of milvexian, releasing a therapeutically effective amount of the milvexian over an extended time.[French]
La présente invention concerne une nouvelle formulation à libération prolongée de milvexian, qui sont utiles pour le traitement ou la prévention d'événements thromboemboliques. L'invention est particulièrement appropriée pour une administration une fois par jour de milvexian, libérant une quantité thérapeutiquement efficace du milvexian sur une durée prolongée.